Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 2/20 | 0.65 |
| ▸ | EGFR | P00533 | 4/20 | 0.62 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.54 |
| ▸ | BRD4 | O60885 | 2/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | PLK1 | P53350 | 2/20 | 0.54 |
| ▸ | TNK2 | Q07912 | 5/20 | 0.51 |
| ▸ | TTK | P33981 | 3/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.49 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.49 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | DCLK2 | Q8N568 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371233 | 0.90 | PTK2 (0.67) | PTK2EGFRBRD4JAK2MAPK7 | |
| SCHEMBL2015974 | 0.88 | EGFR (0.59) | PTK2EGFRALKBRD4JAK2 | |
| SCHEMBL2267020 | 0.82 | JAK3 (0.65) | PTK2EGFRALKJAK2TTK | |
| SCHEMBL20398850 | 0.78 | EGFR (0.75) | EGFRALKBRD4IGF1R | |
| SCHEMBL12371236 | 0.77 | JAK2 (0.58) | PTK2BRD4JAK2MAPK7 | |
| SCHEMBL1706808 | 0.76 | EGFR (1.00) | PTK2EGFRALKJAK2GAK | |
| SCHEMBL17205279 | 0.76 | EGFR (0.72) | EGFRALKJAK2TNK2TTK | |
| SCHEMBL29847131 | 0.74 | TTK (0.70) | EGFRALKBRD4JAK2TNK2 | |
| SCHEMBL16514970 | 0.74 | TTK (0.70) | EGFRALKBRD4JAK2TNK2 | |
| SCHEMBL2120917 | 0.73 | EGFR (0.93) | PTK2EGFRALKJAK2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879028-B2 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879028-B2 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
| WO-2011079231-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | GATEKEEPER PHARMACEUTICAL, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | EGFR, ERBB2, BRCA1 | PTK2 29/4885EGFR 1/4885ALK 911/4885 |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | PTK2 29/4885EGFR 1/4885ALK 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.